OGC O07 Effect of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on survival and recurrence rates in advanced gastric cancer- systematic review and meta analysis

Abstract Background Around 5–20% of patients who undergo surgery for advanced gastric cancer have peritoneal carcinomatosis and 10–54% recurrence after surgery, which is associated with poor prognosis. The role hyperthermic intraperitoneal chemotherapy (HIPEC) in (AGC) not clearly defined. We performed a meta-analysis to assess the safety survival benefit HIPEC AGC. Methods conducted meta-analysis, accordance PRISMA guidelines, clinical trials high-quality non-randomized studies evaluating AGC over last 10 years. were searched PubMed, EMBASE, MEDLINE Cochrane databases between January 2011 December 202. PROSPERO registration number CRD42022310556. Clinical data including overall (OS), recurrence-free survival, rate, complications analyzed extraction using RevMan5.4.The primary endpoint was survival. secondary end points 5 year disease-free post operative complications: myelosuppression, liver dysfunction, intestinal obstruction, leak, mortality. impact on also evaluated. Results Six randomized controlled nonrandomized met inclusion criteria included comprising total 1700 patients. While use did OS at one year, it significantly improved 3 (OR 1.89, 95% CI 1.17–3.05) years 1.87, 1.29–2.71). reduced 0.49, 0.31–0.80) 0.22, 0.11–0.47). increased complications; however, occurrence postoperative renal dysfunction higher group 3.94, 1.85–8.38). 3-year mortality favorable 0.38, 0.18–0.82). Conclusions has evolved past decade. These results suggest that may improve rates reduce AGC, without significant increase complications. any 5-year prognosis dependent patient selection. High quality, multi-centre are needed guide selection developing standardized protocols management this cohort